<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982407</url>
  </required_header>
  <id_info>
    <org_study_id>18-011263</org_study_id>
    <secondary_id>NCI-2019-08426</secondary_id>
    <secondary_id>MC1944</secondary_id>
    <nct_id>NCT03982407</nct_id>
  </id_info>
  <brief_title>68 Ga PSMA PET/MRI for Hepatocellular Carcinoma</brief_title>
  <official_title>Pilot Study of Integrated Time-of-Flight (TOF) 68 GA-PSMA - Gadoxetate PET/MR for Evaluation of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajit H. Goenka, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to investigate the evaluate to use of a drug/radiopharmaceutical called&#xD;
      Gallium-68 PSMA-11 (68Ga-PSMA-11) for use in PET/MRI evaluation of hepatocellular carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective pilot proof-of-concept single-center study. Primary Objective Using&#xD;
      surgical histopathology as the reference standard, the investigators intend to achieve the&#xD;
      following objectives in adult subjects with Hepatocellular Carcinoma (HCC) undergoing&#xD;
      surgical resection or transplant:&#xD;
&#xD;
        1. To demonstrate the feasibility of 68Ga-PSMA-PET/MRI for imaging patients with HCC&#xD;
&#xD;
        2. To estimate the sensitivity of SUVmax on PSMA PET for identification of LI-RADSÂ® 5&#xD;
           (definitely HCC) observations or biopsy proven HCC(s).&#xD;
&#xD;
        3. To perform a Radiology-Pathology correlation of PSMA uptake at PET with HCC tumor PSMA&#xD;
           immunostaining, tumor pathology features, and signal and enhancement characteristics at&#xD;
           MRI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of PSMA PET-MR for identification of intra and extrahepatic hepatocellular carcinoma in patients</measure>
    <time_frame>18 months</time_frame>
    <description>Sensitivity of PSMA PET-MRI for detection of LI-RADS 5 (definitely HCC) lesions on a per-lesion basis with histopathology as the gold standard. We will perform a Radiologic-pathologic correlation comparing HCC PSMA SUVmax with tumor PSMA immunostaining positivity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ga68 PSMA PET-MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA-11 PET/MRI</intervention_name>
    <description>The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.</description>
    <arm_group_label>Ga68 PSMA PET-MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at risk for HCC with either an imaging diagnosis of HCC by ceCT or ceMRI&#xD;
             (LI-RADS 5) confirmed by a board-certified abdominal radiologist or biopsy-proven HCC&#xD;
             confirmed by a hepatobiliary pathologist&#xD;
&#xD;
          -  No prior treatment for HCC&#xD;
&#xD;
          -  Subjects who are expected to undergo surgical resection of the hepatic lesion(s)&#xD;
             and/or liver transplant&#xD;
&#xD;
          -  Male or female with age greater than 18 years, with the capacity to give informed&#xD;
             consent and willingness to provide a written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects requiring emergent surgery for a ruptured/bleeding HCC&#xD;
&#xD;
          -  Bilirubin &gt; 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast&#xD;
             agent&#xD;
&#xD;
          -  Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of&#xD;
             the PET scan.&#xD;
&#xD;
          -  Subjects with higher than the weight/size limitations of PET/MRI scanner.&#xD;
&#xD;
          -  Subjects with contraindication to MRI including: Subjects who have a heart pacemaker,&#xD;
             subjects who have a metallic foreign body (metal sliver) in their eye, or who have an&#xD;
             aneurysm clip in their brain, subjects who have implanted devices with magnets,&#xD;
             subjects who have other implanted electronic devices, subjects who have deep brain&#xD;
             stimulator, subjects who have vagal nerve stimulator, subjects with cochlear (ear) or&#xD;
             auditory implants&#xD;
&#xD;
          -  Subjects with history of allergic response to radiocontrast media&#xD;
&#xD;
          -  Subjects with known history of claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajit H Goenka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ajit H. Goenka, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

